Amneal Announces Approval of Rivastigmine Transdermal System

BRIDGEWATER, N.J., Jan. 14, 2019 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 m... Biopharmaceuticals, Drug Delivery, Generics, FDA Amneal Pharmaceuticals, Rivastigmine, Transdermal
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news